ES2532089T3 - GH e IGF-1 para el tratamiento de trastornos del crecimiento - Google Patents
GH e IGF-1 para el tratamiento de trastornos del crecimiento Download PDFInfo
- Publication number
- ES2532089T3 ES2532089T3 ES06784529.7T ES06784529T ES2532089T3 ES 2532089 T3 ES2532089 T3 ES 2532089T3 ES 06784529 T ES06784529 T ES 06784529T ES 2532089 T3 ES2532089 T3 ES 2532089T3
- Authority
- ES
- Spain
- Prior art keywords
- igf
- subject
- idb
- growth
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title abstract description 45
- 238000011282 treatment Methods 0.000 title abstract description 10
- 208000037824 growth disorder Diseases 0.000 title abstract description 7
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title description 36
- 108010051696 Growth Hormone Proteins 0.000 abstract description 65
- 102000018997 Growth Hormone Human genes 0.000 abstract description 65
- 239000000122 growth hormone Substances 0.000 abstract description 61
- 230000036765 blood level Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 13
- 102000013275 Somatomedins Human genes 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 230000011664 signaling Effects 0.000 abstract description 7
- 238000011221 initial treatment Methods 0.000 abstract description 3
- 101150088952 IGF1 gene Proteins 0.000 abstract description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 40
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 20
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- 230000037396 body weight Effects 0.000 description 11
- 102000002265 Human Growth Hormone Human genes 0.000 description 8
- 108010000521 Human Growth Hormone Proteins 0.000 description 8
- 239000000854 Human Growth Hormone Substances 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 7
- 208000006302 Laron syndrome Diseases 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 102400001066 Growth hormone-binding protein Human genes 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 101710115821 Flavin reductase (NADPH) Proteins 0.000 description 3
- 102100020948 Growth hormone receptor Human genes 0.000 description 3
- 108010068542 Somatotropin Receptors Proteins 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010013127 Met-human growth hormone Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000020221 Short stature Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229940063149 nutropin Drugs 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 108700031632 somatrem Proteins 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000015752 Growth delay due to insulin-like growth factor type 1 deficiency Diseases 0.000 description 1
- 208000016857 Growth hormone insensitivity syndrome Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108700038030 Insulin-Like Growth Factor I Deficiency Proteins 0.000 description 1
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000023109 Prominent forehead Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000022967 Short stature due to partial GHR deficiency Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000022266 body dysmorphic disease Diseases 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009247 menarche Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 108010033419 somatotropin-binding protein Proteins 0.000 description 1
- 229960003259 somatrem Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68761705P | 2005-06-02 | 2005-06-02 | |
| US687617P | 2005-06-02 | ||
| PCT/US2006/021282 WO2006130769A2 (en) | 2005-06-02 | 2006-06-01 | Methods for treatment of growth disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2532089T3 true ES2532089T3 (es) | 2015-03-24 |
Family
ID=37482318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06784529.7T Active ES2532089T3 (es) | 2005-06-02 | 2006-06-01 | GH e IGF-1 para el tratamiento de trastornos del crecimiento |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8158582B2 (enExample) |
| EP (1) | EP1901770B1 (enExample) |
| JP (2) | JP2008545752A (enExample) |
| ES (1) | ES2532089T3 (enExample) |
| WO (1) | WO2006130769A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2689549A1 (en) | 2007-06-08 | 2008-12-18 | Massachusetts Institute Of Technology | Igf for the treatment of rett syndrome and synaptic disorders |
| US8759299B2 (en) | 2009-07-22 | 2014-06-24 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59 |
| CA2780554C (en) * | 2009-11-17 | 2017-08-15 | Ipsen Pharma S.A.S. | Formulation for hgh and rhigf-1 combination |
| EP3597178A1 (en) * | 2012-06-21 | 2020-01-22 | Phosphorex Inc. | Nanoparticles of indirubin, derivatives thereof and methods of making and using same |
| WO2016100528A1 (en) * | 2014-12-16 | 2016-06-23 | Puretein Bioscience Llc. | Methods for increasing serum igf-1 in an animal |
| KR20250025051A (ko) * | 2017-08-24 | 2025-02-20 | 사노피 | 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374620A (en) | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
| US5126324A (en) | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US5681814A (en) | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
| SE9002731D0 (sv) | 1990-08-24 | 1990-08-24 | Kabivitrum Ab | Product comprising growth factor |
| TW267102B (enExample) | 1992-03-13 | 1996-01-01 | Ciba Geigy | |
| IL106546A0 (en) | 1993-08-01 | 1993-12-08 | Zvi Rozenberg | Apparatus for a bicycle and a two wheel vehicle |
| US5824642A (en) * | 1994-04-07 | 1998-10-20 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
| US5646113A (en) * | 1994-04-07 | 1997-07-08 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
| US5741776A (en) | 1995-05-22 | 1998-04-21 | Genentech, Inc. | Method of administration of IGF-I |
| ATE536186T1 (de) * | 2003-09-12 | 2011-12-15 | Tercica Inc | Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel |
| CA2780554C (en) | 2009-11-17 | 2017-08-15 | Ipsen Pharma S.A.S. | Formulation for hgh and rhigf-1 combination |
-
2006
- 2006-06-01 WO PCT/US2006/021282 patent/WO2006130769A2/en not_active Ceased
- 2006-06-01 EP EP06784529.7A patent/EP1901770B1/en not_active Not-in-force
- 2006-06-01 US US11/915,978 patent/US8158582B2/en not_active Expired - Fee Related
- 2006-06-01 ES ES06784529.7T patent/ES2532089T3/es active Active
- 2006-06-01 JP JP2008514854A patent/JP2008545752A/ja active Pending
-
2012
- 2012-03-12 US US13/417,983 patent/US8440616B2/en not_active Expired - Fee Related
-
2014
- 2014-03-05 JP JP2014043298A patent/JP2014129405A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US8158582B2 (en) | 2012-04-17 |
| EP1901770A2 (en) | 2008-03-26 |
| US8440616B2 (en) | 2013-05-14 |
| EP1901770A4 (en) | 2010-11-03 |
| WO2006130769A9 (en) | 2007-01-18 |
| US20100137200A1 (en) | 2010-06-03 |
| EP1901770B1 (en) | 2014-12-24 |
| JP2008545752A (ja) | 2008-12-18 |
| JP2014129405A (ja) | 2014-07-10 |
| WO2006130769A3 (en) | 2009-04-16 |
| WO2006130769A2 (en) | 2006-12-07 |
| US20120232009A1 (en) | 2012-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Farr et al. | Leptin applications in 2015: what have we learned about leptin and obesity? | |
| Hummer et al. | Hyperprolactinaemia and antipsychotic therapy in schizophrenia | |
| Mahan et al. | Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement | |
| US8946152B2 (en) | Method of treating parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen | |
| US20100004166A1 (en) | Endothelin and Endothelin Receptor Agonists in the Treatment of Metabolic Diseases | |
| BRPI0712147A2 (pt) | polipeptìdeos estabilizados do fator do crescimento insulina-like | |
| EA013121B1 (ru) | Амилин и агонисты амилина для лечения психиатрических заболеваний и расстройств | |
| Page-Wilson et al. | Hypothalamic obesity in patients with craniopharyngioma: treatment approaches and the emerging role of gastric bypass surgery | |
| Sartorio et al. | Adults with childhood‐onset growth hormone deficiency: effects fo growth harmone treatment on cardiac structure | |
| ES2532089T3 (es) | GH e IGF-1 para el tratamiento de trastornos del crecimiento | |
| Keating | Mecasermin | |
| Fine | Stimulating growth in uremic children | |
| CN105072909A (zh) | 应用控制食欲不振的化合物的组合物和方法 | |
| JP7120718B2 (ja) | 体重増加用化合物の長期使用のための組成物と方法 | |
| JP2009538824A (ja) | 精神疾患及び障害治療用アミリン及びアミリンアゴニスト | |
| Clark | Recombinant insulin-like growth factor-1 as a therapy for IGF-1 deficiency in renal failure | |
| Lyle et al. | Human growth hormone and anti-aging | |
| Chertman et al. | Growth hormone in aging | |
| US20020156019A1 (en) | Method of optimizing growth hormone replacement | |
| JP6977979B2 (ja) | 神経損傷治療又は予防用医薬 | |
| JP2007519669A (ja) | 脂肪異栄養症を治療するための方法及び組成物 | |
| Chernausek | Treatment of insulin-like growth factor deficiency with IGF-I: studies in humans | |
| Carroll et al. | Growth hormone therapy may benefit protein metabolism in mitochondrial encephalomyopathy | |
| Petriczko et al. | Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Pediatric Growth Hormone Deficiency (PGHD) over 12 to 24 Months on Treatment | |
| Dooley et al. | Human mecasermin: a review of its use in amyotrophic lateral sclerosis |